Therapeutic development for hypertension by targeting the peptide-mediated blood pressure control
Biochemical Pharmacology · 2026-09 · 251 · 118115
DOI: 10.1016/j.bcp.2026.118115 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Akira Sato und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Japan. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure, Peptides. Die Arbeit nennt 156 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Blood pressure (BP) is controlled by coordinated actions of the neural, hormonal, renal, and vascular systems. Several endogenous peptides, such as angiotensin II (AngII), endothelin-1 and natriuretic peptides, which are usually generated from precursor proteins by enzymatic cleavage, are crucial to regulate the systems. Dysregulation of these tightly organized systems leads to hypertension and related diseases. Conventional anti-hypertensive therapies often fail to control hypertension or suppress hypertension-related pathologies, highlighting the need for novel therapeutic agents for managing hypertension. Both endogenous and exogenous peptides are highly selective to their targets and have adjustable pharmacokinetics, low toxicity, and weak immune responses. These characteristics may prove beneficial when investigating potential peptide-based anti-hypertensive medicine. Recent studies from our and other research groups have challenged and proposed newly identified peptides, artificially designed peptides, and peptidases that catalyze the vasoconstrictor peptide hormone AngII. These agents have all been shown to reduce BP in hypertensive animal models. In this review article, we have summarized these findings with the aim to promote understanding of the effects of peptides and peptidases on BP control. These data suggest that further development of innovative anti-hypertensive drugs may be productive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Japan.
- Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Japan. Electronic address: hogita@belle.shiga-med.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sato, A., & Ogita, H. (2026). Therapeutic development for hypertension by targeting the peptide-mediated blood pressure control. Biochemical Pharmacology, 251, 118115. https://doi.org/10.1016/j.bcp.2026.118115
Vancouver
Sato A, Ogita H. Therapeutic development for hypertension by targeting the peptide-mediated blood pressure control. Biochemical Pharmacology. 2026;251:118115. doi:10.1016/j.bcp.2026.118115
BibTeX
@article{Sato2026,
author = {Sato, Akira and Ogita, Hisakazu},
title = {Therapeutic development for hypertension by targeting the peptide-mediated blood pressure control},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118115},
doi = {10.1016/j.bcp.2026.118115}
}
EUVIMED